Among US adults, higher consumption of dietary cholesterol or eggs was significantly associated with higher risk of incident CVD and all-cause mortality in a dose-response manner.
EPCCS 2019 Read an impression of the presentation of prof. Van der Meer, on the latest recommendations on management of HF, including important aspects to consider in patients with comorbidities.
EPCCS 2019 In a comprehensive talk, professor Hobbs considered a range of aspects relevant to the management of patients with atrial fibrillation (AF), the most common cardiac arrhythmia. Read an impression
EPCCS 2019 In case-based discussions, various complexities of management of patients with multimorbity and polypharmacy were discussed, and strategies to deal with this were exchanged.
EPCCS 2019 Read impressions of the updates on stroke prevention in AF, hypertension, HF and CV risk in diabetes, with emphasis on challenges faced in patients with multimorbidities.
Prior to the Annual CV Summit, country representatives of the EPCCS Council gathered in Lisbon to discuss the next necessary steps to expand our European network of GP’s.
ACC 2019 The randomized INFINITY trial showed a reduction in accrual of subcortical white matter disease in older people treated to 130 vs. 145 mmHg, but that did not improve mobility and cognitive function.
ACC 2019 Results of the CLEAR Wisdom trial showed that bempedoic acid lowered LDL-c in high CV risk patients with elevated LDL-c levels who are on maximally tolerated statin and/or other lipid-modifying therapies.
ACC 2019 Dr. Khera explains how the guideline writing committee aimed to compose a comprehensive document to cover all facets of prevention. He discusses some recommendations, including a clear message on aspirin.
ACC 2019 Dr. Arnett explains three recommendations that should help implement all advice: a team-based and patient-centered approach and attention for social determinants of health.
ACC 2019 Dr. Valentine chaired the press conference on the Apple Heart Study. He summarizes the results and the response to the AF-screening results obtained with Apple Watch.
ACC 2019 Icosapent ethyl reduces total ischemic events and first and recurrent events compared to placebo. Prof Bhatt explains the results of the REDUCE-IT trial and what this means for high risk patients.